Best Practices in the Curation and Use of Real-world Data in the Regulatory Pathway
← Characteristics and Outcomes of Patients Receiving Sequential Bruton’s Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice SettingReal-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression →